董事Luke Evnin报告在三天内出售了 Werewolf Therapeutics, Inc. (NASDAQ:HOWL) 的普通股，交易总额约为61,787美元。这些交易发生在2026年1月13日至1月15日期间，价格范围在0.55美元至0.57美元之间。根据 InvestingPro 数据，这家市值仅为2718万美元的微型生物技术公司在过去一年中股价下跌了超过60%。

Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.14 per share a year ago. These ...

Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Werewolf Therapeutics (HOWL – Research Report) yesterday and set a price target of $9.00. The company’s shares closed ...

Werewolf Therapeutics Inc HOWL released preliminary results from initial monotherapy dose-escalation cohorts of an ongoing Phase 1/1b trial of WTX-124 in patients with advanced or metastatic solid ...

Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to ...

Werewolf Therapeutics (NASDAQ:HOWL) just reported results for the second quarter of 2024. Werewolf Therapeutics reported earnings per share of -43 cents. This was below the analyst estimate for EPS of ...

Werewolf Therapeutics is developing a "conditionally activated" interleukin-2 (IL-2) drug for the treatment of stage IV melanoma and metastatic cancers. The drug aims to deliver therapeutic doses of ...

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) is anticipated to issue its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce ...